新辅助度伐利尤单抗联合顺铂/吉西他滨治疗后膀胱切除术与盆腔淋巴结清扫的安全性和质量
SAKK 06/17为开放标签单臂II期试验,纳入61例符合顺铂条件的cT2-T4a cN0-1可手术尿路上皮肌层浸润性膀胱癌或上尿路癌患者,接受新辅助顺铂/吉西他滨和度伐利尤单抗后手术。50例接受根治性膀胱切除术与盆腔淋巴结清扫,中位淋巴结数29枚,≥III级术后并发症12例(24%),结论支持该方案手术安全性,但协议定义的淋巴结清扫范围与完整性存在患者间差异。
要点
- 50例接受根治性膀胱切除术与盆腔淋巴结清扫,中位清扫淋巴结数为29枚(IQR 23-38)。
- 无术中并发症记录,≥III级术后并发症见于12例(24%)。
- 闭孔窝(双侧)和左髂外区域完全淋巴结清扫为100%,右髂外和髂内区域为49例(98%),右和左骶前分别为39例(78%)和38例(76%)。
核心结论
- 本研究支持肌层浸润性膀胱癌患者接受新辅助化疗-免疫治疗后行根治性膀胱切除术与盆腔淋巴结清扫的手术安全性。
- 协议定义的盆腔淋巴结清扫范围和完整性在患者间存在差异,凸显沟通和监测手术模板的必要性。
研究设计与样本
- SAKK 06/17为开放标签单臂II期试验,纳入61例符合顺铂条件的cT2-T4a cN0-1可手术尿路上皮肌层浸润性膀胱癌或上尿路癌患者。
- 患者接受新辅助顺铂/吉西他滨和度伐利尤单抗后手术,通过术中照片集中审核进行前瞻性手术质量评估,术后并发症采用Clavien-Dindo分类评估,数据描述性分析。
主要发现
- 50例患者接受根治性膀胱切除术与盆腔淋巴结清扫,所有患者均接受新辅助化疗-免疫治疗。
- 中位(四分位距)清扫淋巴结数为29(23-38)枚,无术中并发症记录。
- ≥III级术后并发症报告于12例患者(24%)。
- 闭孔窝(双侧)和左髂外区域完全淋巴结清扫为100%;右髂外和髂内区域为49例(98%);右和左骶前分别为39例(78%)和38例(76%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report on the surgical safety and quality of pelvic lymph node dissection (PLND) in patients treated with radical cystectomy (RC) and PLND for muscle-invasive bladder cancer (MIBC) after neoadjuvant chemo-immunotherapy. PATIENTS AND METHODS: The Swiss Group for Clinical Cancer Research (SAKK) 06/17 was an open-label single-arm phase II trial including 61 cisplatin-fit patients with clinical stage (c)T2-T4a cN0-1 operable urothelial MIBC or upper urinary tract cancer. Patients received neoadjuvant cisplatin/gemcitabine and durvalumab followed by surgery. Prospective quality assessment of surgeries was performed via central review of intraoperative photographs. Postoperative complications were assessed using the Clavien-Dindo Classification. Data were analysed descriptively. RESULTS: A total of 50 patients received RC and PLND. All patients received neoadjuvant chemo-immunotherapy. The median (interquartile range) number of lymph nodes removed was 29 (23-38). No intraoperative complications were registered. Grade ≥III postoperative complications were reported in 12 patients (24%). Complete nodal dissection (100%) was performed at the level of the obturator fossa (bilaterally) and of the left external iliac region; in 49 patients (98%) at the internal iliac region and at the right external iliac region; in 39 (78%) and 38 (76%) patients at the right and left presacral level, respectively. CONCLUSION: This study supports the surgical safety of RC and PLND following neoadjuvant chemo-immunotherapy in patients with MIBC. The extent and completeness of protocol-defined PLND varies between patients, highlighting the need to communicate and monitor the surgical template.
引用
- Afferi L, Spahn M, Hayoz S, et al. Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine. BJU Int. 2024. PMID: 38456541. doi:10.1111/bju.16318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。